Latest News
Rocket Lab Corp (NASDAQ: RKLB) shares are trading lower Monday morning as investors look ahead to this week's earnings report.
Via Benzinga · February 23, 2026
While Microsoft has underperformed relative to the Dow over the past year, Wall Street analysts maintain a bullish outlook on the stock’s prospects.
Via Barchart.com · February 23, 2026
Via Talk Markets · February 23, 2026
Trump gives Iran 15 days to make a deal or face consequences, but considering strikes; Iran warns against aggression and prepares for defense.
Via Benzinga · February 23, 2026
Via Benzinga · February 23, 2026
Via Talk Markets · February 23, 2026
GeneDx Holdings Corp (NASDAQ:WGS) Reports Mixed Q4 2025 Results, Stock Falls Despite Strong 2026 Outlookchartmill.com
Via Chartmill · February 23, 2026
Axsome Therapeutics Inc (NASDAQ:AXSM) Reports Q4 2025 Results, Meeting Revenue Forecasts but Posting Wider Losschartmill.com
Via Chartmill · February 23, 2026
Kratos Defense stock is in the spotlight Monday ahead of the company's fourth-quarter earnings report after the market closes.
Via Benzinga · February 23, 2026
LONDON/HOUSTON — The global oil market has entered a period of extreme turbulence as of February 23, 2026, with crude prices swinging violently between two opposing forces. On one side, a mounting geopolitical risk premium—driven by a potential military escalation between the U.S. and Iran—is threatening to
Via MarketMinute · February 23, 2026
The U.S. labor market continues to exhibit a complex duality of resilience and cooling, as the latest Department of Labor report revealed that initial jobless claims fell to 227,000 for the week ending February 7, 2026. While the figure came in slightly above Wall Street’s expectations of
Via MarketMinute · February 23, 2026
Stepan Co. (NYSE:SCL) Stock Plummets 16% After Q4 Earnings Misschartmill.com
Via Chartmill · February 23, 2026
Lincoln Educational Services (NASDAQ:LINC) Surges on Strong Q4 Earnings Beat and Upbeat 2026 Guidancechartmill.com
Via Chartmill · February 23, 2026

Spyre Therapeutics develops preclinical monoclonal antibody therapies targeting inflammatory bowel disease and related conditions.
Via The Motley Fool · February 23, 2026
These companies just turned in fourth-quarter earnings reports that should have investors salivating at their upside in 2026 and beyond.
Via The Motley Fool · February 23, 2026
While Fair Isaac has considerably trailed the S&P 500 over the past 52 weeks, Wall Street analysts maintain a moderately optimistic outlook about the stock’s prospects.
Via Barchart.com · February 23, 2026
In a landmark decision for the cardiovascular treatment landscape, the European Commission (EC) officially granted marketing authorization to Cytokinetics, Inc. (Nasdaq: CYTK) on February 17, 2026, for its innovative cardiac drug, MYQORZO (aficamten). The approval clears the way for the treatment of adult patients suffering from symptomatic obstructive hypertrophic cardiomyopathy
Via MarketMinute · February 23, 2026
The financial landscape of 2026 has opened with a dramatic shift in market leadership, as small-cap stocks stage a historic rally that has left large-cap tech giants in the rearview mirror. After years of dominance by a handful of "Magnificent 7" companies, the tide has turned toward the "median stock,
Via MarketMinute · February 23, 2026
A positive surprise this quarter could silence the skeptics.
Via Barchart.com · February 23, 2026
What's going on in today's session: S&P500 gap up and gap down stockschartmill.com
Via Chartmill · February 23, 2026
The midstream oil and gas company has scheduled its fourth-quarter earnings on Feb. 23.
Via The Motley Fool · February 23, 2026
The S&P 500 (NYSE:SPY) could plunge to 3,500 by 2028 if the AI revolution succeeds too well, according to a chilling “pre-mortem” scenario released by Ci
Via Benzinga · February 23, 2026
Here's a look at the earnings calendar for the week ahead, including reports from Nvidia, Joby, CoreWeave, Salesforce, Lucid and more.
Via Benzinga · February 23, 2026
Opendoor stock soared on Friday as the iBuyer reports better-than-expected Q4 earnings. Still, there’s reason to avoid buying OPEN shares into the post-release strength.
Via Barchart.com · February 23, 2026
Although Everest Group has lagged the S&P 500 over the past year, Wall Street analysts maintain a moderately optimistic outlook about the stock’s prospects.
Via Barchart.com · February 23, 2026
In a definitive move to solidify its position as a leader in the environmental services sector, Republic Services Inc. (NYSE: RSG) released its full-year 2026 financial guidance on February 17, 2026, outlining a strategic pivot toward high-margin municipal contracts and an aggressive expansion of its waste-to-energy portfolio. The company, which
Via MarketMinute · February 23, 2026
Shares of InMode Ltd (NASDAQ: INMD) are trading lower Monday morning after the Israeli medical technology company said a special independent transaction committee has ended its strategic review without pursuing any deal.
Via Benzinga · February 23, 2026
Gov. Gavin Newsom considering 2028 White House run, influenced by son's text. Rising national profile through opposition to Trump.
Via Benzinga · February 23, 2026
In a tale of two markets, Caesars Entertainment (NASDAQ:CZR) reported a fourth-quarter earnings result that underscored a profound shift in the gaming giant’s financial architecture. While the glitz and glamour of the Las Vegas Strip showed signs of a post-pandemic "normalization"—marked by cooling hotel rates and lower
Via MarketMinute · February 23, 2026
The U.S. Food and Drug Administration has granted premarket approval for Allurion’s Gastric Balloon System with the swallowable Allurion Smart Capsule.
Via Stocktwits · February 23, 2026
These stocks are gapping in today's sessionchartmill.com
Via Chartmill · February 23, 2026
These Canadian growth stocks are backed by fundamentally strong businesses and are witnessing solid demand.
Via The Motley Fool · February 23, 2026

Centessa Pharmaceuticals develops clinical-stage therapies for rare and serious diseases, leveraging a portfolio approach in biopharma.
Via The Motley Fool · February 23, 2026
In a pivotal moment for the consumer health landscape, Kenvue (NYSE: KVUE) has reported a robust set of fourth-quarter results for 2025, signaling a successful turnaround and strategic resilience just months after the announcement of its blockbuster merger. On February 17, 2026, the company revealed that its Q4 net sales
Via MarketMinute · February 23, 2026
Palo Alto Networks (NASDAQ: PANW) has once again redefined the cybersecurity landscape with its fiscal second-quarter 2026 results, proving that the controversial "platformization" strategy launched two years ago is bearing significant fruit. Despite a minor post-earnings dip in share price due to integration costs associated with its massive $25 billion
Via MarketMinute · February 23, 2026
In a definitive sign that the medical technology sector has moved past its post-pandemic stagnation, Medtronic (NYSE: MDT) reported its strongest enterprise revenue growth in ten quarters for the third fiscal quarter of 2026. On February 17, 2026, the Dublin-based medical device giant announced total revenue of $9.017 billion,
Via MarketMinute · February 23, 2026
As of February 23, 2026, ONEOK, Inc. (NYSE: OKE) stands as a titan of the North American midstream energy landscape. In the wake of a historic three-year consolidation phase—marked by the transformative acquisition of Magellan Midstream Partners and the subsequent 2024 integrations of EnLink Midstream and Medallion Midstream—ONEOK has evolved from a pure-play natural gas [...]
Via Finterra · February 23, 2026
With yields of up to 6%, these three reliable income generators are still attractive buys as February draws to a close.
Via The Motley Fool · February 23, 2026

Stepan (SCL) Q4 2025 Earnings Call Transcript
Via The Motley Fool · February 23, 2026
As of February 23, 2026, the biotechnology landscape has shifted away from the speculative fervor of the early 2020s toward a demand for commercial execution and sustainable revenue. Standing at the center of this transformation is Axsome Therapeutics (Nasdaq: AXSM), a mid-cap CNS (Central Nervous System) specialist that has successfully navigated the "valley of death" [...]
Via Finterra · February 23, 2026
The enterprise software sector, long the crown jewel of Wall Street’s growth portfolio, is currently grappling with a fundamental identity crisis that has wiped out nearly $1 trillion in market value since the start of the year. Investors have rapidly soured on the traditional "Software-as-a-Service" (SaaS) model, fearing that
Via MarketMinute · February 23, 2026
As of February 23, 2026, Hims & Hers Health, Inc. (NYSE: HIMS) finds itself at a critical crossroads that has sent shockwaves through the telehealth and pharmaceutical sectors. Once the darling of the "personalized medicine" movement, the company is currently grappling with extreme stock volatility following a series of aggressive regulatory maneuvers and high-stakes litigation [...]
Via Finterra · February 23, 2026

Nuvalent develops targeted cancer therapies, advancing clinical candidates for patients with limited treatment options in oncology.
Via The Motley Fool · February 23, 2026
Precious metals experienced a dramatic breakout during Monday’s trading session on February 23, 2026, as a "perfect storm" of domestic legal battles and rising military tensions in the Middle East sent investors scurrying for safety. Gold futures surged more than 2%, breaching the psychologically significant $5,100 level, while
Via MarketMinute · February 23, 2026
On this Monday, February 23, 2026, the global leader in pizza delivery finds itself in an enviable but high-stakes position. As Domino’s Pizza, Inc. (NYSE: DPZ) releases its fourth-quarter and full-year 2025 earnings report this morning, the market is closely watching to see if the "Hungry for MORE" strategy—launched by CEO Russell Weiner in late [...]
Via Finterra · February 23, 2026
Tilray Brands is expanding its business at a rapid clip, but there are risks associated with this growth effort.
Via The Motley Fool · February 23, 2026
The U.S. bond market witnessed a significant shift in sentiment this February, as the benchmark 10-year Treasury yield drifted down to approximately 4.09%, marking a notable retreat from the highs seen in late 2025. This downward move reflects a growing consensus among investors that the long-standing battle against
Via MarketMinute · February 23, 2026
As of February 23, 2026, the energy sector’s eyes are fixed on Midland, Texas. Diamondback Energy (NASDAQ: FANG), the undisputed heavyweight champion of Permian Basin independent producers, has just released its fourth-quarter 2025 earnings. In a market defined by fluctuating crude prices and a fierce industry-wide mandate for capital discipline, Diamondback stands as a case [...]
Via Finterra · February 23, 2026
On February 23, 2026, LyondellBasell (NYSE: LYB) stands at a critical crossroads. Once celebrated as a high-yield dividend powerhouse of the petrochemical sector, the company has spent the early months of 2026 aggressively restructuring its identity. Today’s market developments—including a major recalibration of its 2030 sustainability targets and a significant shift in capital allocation—signal a [...]
Via Finterra · February 23, 2026